Ratings GemPharmatech Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
11.65 ^CNY	+2.82%		+7.87%	-42.18%

26/04	GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023.	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	ESG Refinitiv
GEMPHARMATECH CO., LTD.	-42.18%	660M	-
MODERNA, INC.	+43.36%	54.64B	B-
IQVIA HOLDINGS INC.	-5.31%	39.92B	B
LONZA GROUP AG	+37.52%	38.82B	A
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B	B-
CELLTRION, INC.	-12.56%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B	B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B	B+
BIO-TECHNE CORPORATION	+0.04%	12.16B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality